Fig. 6: Comparative analysis of the attributed PGx levels of the Swiss DLs with those of other regulatory authorities, namely the Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Health Care Service Cooperation (HSCS), and the Pharmaceutical and Medical Devices Agency (PMDA). | The Pharmacogenomics Journal

Fig. 6: Comparative analysis of the attributed PGx levels of the Swiss DLs with those of other regulatory authorities, namely the Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Health Care Service Cooperation (HSCS), and the Pharmaceutical and Medical Devices Agency (PMDA).

From: Pharmacogenetic information in Swiss drug labels – a systematic analysis

Fig. 6

Each drug was included in the schematic of A, C, E, and G linking its PGx level indicated by the respective DL of the publishing agency to visualize heterogeneity. In B, D, F and H the number of drugs in each category is indicated by the width of the violin.

Back to article page